Edwards Lifesciences Corporation (NYSE:EW) shares are trading higher on Thursday. Stifel analyst Rick Wise upgraded Edwards from Hold to Buy, raising the price forecast to $90 from $75. Wise suggests ...

Edwards Lifesciences (NYSE: EW) stock rises after Stifel upgrades to Buy, citing potential for TAVR growth acceleration in 2025. Read more here.

CABG plus surgical aortic valve replacement for treatment of coronary disease and aortic stenosis was associated with better 5-year outcomes vs. PCI plus transcatheter aortic valve replacement in ...

Our Bureau, Mumbai Thursday, January 30, 2025, 15:15 Hrs [IST] ...

Stifel analysts upgraded Edwards Lifesciences (NYSE:EW) stock from Hold to Buy, citing potential growth acceleration in the Transcatheter Aortic Valve Replacement (TAVR) market. The firm also ...

Stifel analyst Rick Wise upgraded Edwards Lifesciences (EW) to Buy from Hold with a price target of $90, up from $75. The firm said that TAVR, ...

Middle-aged adults who need an aortic valve replacement fare better with mechanical devices than with the valves made from animal tissues that they currently most often receive, U.S. researchers ...

Australia’s Therapeutic Goods Administration posted a draft guidance dealing with non-mandatory audits for premarket applications, which says that a transcatheter aortic valve replacement device that ...

Navitor Vision enhances visibility and precision in TAVI procedures, offering a less invasive alternative to surgical aortic ...

The Navitor Vision, Abbott's latest TAVI system, is designed to improve accuracy during implantation and enhance visibility ...

Annual Meeting reveals that mechanical aortic valve replacements (AVRs) provide significant long-term survival benefits for ...